Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies

21-Aug-2017 Intellasia | BusinessWire | 6:30 AM Print This Post
  • Agreement encompasses joint funding and co-development
  • Immediate program focus on TAK-671, a therapeutic candidate
    intended to address unmet need in severe acute pancreatitis.

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. announced today that it has entered into a
strategic collaboration agreement with Takeda Pharmaceutical Company
Limited (TSE:
) to jointly fund and co-develop multiple novel biologic
therapies in unmet disease areas. The two companies will immediately
begin working on the program’s first therapeutic candidate, TAK-671,
which is intended to treat severe acute pancreatitis.

“Takeda’s extensive knowledge and expertise in drug development makes
the company an ideal partner for us as we open a new chapter at Samsung
Bioepis,” said Christopher Hansung Ko, President and CEO, Samsung
Bioepis. “Five years ago, we entered the biopharmaceutical industry with
a strong determination to transform the way therapies are brought to
patients by replacing legacy processes with new and innovative ones.
Together with Takeda, we look forward to realizing this vision by
accelerating the development of effective therapies for patients who are
currently without a viable treatment option.”

The risk-sharing partnership brings together Samsung Bioepis’ agile
biologics development platform with Takeda’s best-in-class experts in
drug development to co-fund and collaboratively develop innovative
therapies representing meaningful value to patients who need them.
Additional terms of the collaboration are not being disclosed.

“At Takeda, we think differently – and creatively – about what makes a
partnership successful and look to build on our strengths by
collaborating with partners who have complementary expertise,” said
Daniel Curran, M.D., Head, Center for External Innovation, Takeda. “This
collaboration with Samsung Bioepis does that, by combining our unique
capabilities in development and manufacturing along with fresh and
innovative clinical approaches, we will maximize the potential for
successful introduction of important medicines to patients.”

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company
committed to realizing healthcare that is accessible to everyone.
Through innovations in product development and a firm commitment to
quality, Samsung Bioepis aims to become the world’s leading
biopharmaceutical company. Samsung Bioepis continues to advance a broad
pipeline of biosimilar candidates that includes six first-wave
candidates that cover the therapeutic areas of immunology, oncology and
diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics
and Biogen. For more information, please visit:


Media Contacts:
Samsung Bioepis
Mingi Hyun
[email protected]
Schlemm – USA
[email protected]


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.